Clinical Trials Browser

lenvatinib × Thoracic × 90 days × Clear all

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04938817 2026-06-01

KEYNOTE-B98

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05384015 2026-04-30

PEERS

Phase 2 Active not recruiting

Lung Neoplasms

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular